Bicycle Therapeutics is scaling back development of its Nectin-4–targeting toxin conjugate zelenectide pevedotin in metastatic urothelial cancer (mUC) after regulators said the current Phase II/III Duravelo-2 registrational trial design is “no longer considered acceptable as an approval path,” prompting a conversion to a randomized Phase II. The company is also cutting ~30% of staff and shifting focus to its EphA2 program BT5528 (nuzefatide pevedotin).

Why It Matters To Oncology

• Regulatory feedback can abruptly invalidate a registrational strategy even with an active trial, forcing sponsors to redesign endpoints, comparators, and/or statistical powering for metastatic disease settings.

• Nectin-4 remains a clinically validated target in mUC, but this update underscores that target validation doesn’t de-risk the approval pathway for a specific modality (here, a Bicycle toxin conjugate) or trial design.

• The pivot concentrates R&D on EphA2 (BT5528), a target of interest across multiple solid tumors, including ongoing Phase II work in metastatic pancreatic ductal adenocarcinoma.

The Financials

• Headcount reduction: ~30% (following a prior ~25% cut last year).

• Runway impact: Bicycle says the reset extends cash runway by ~2 years, into 2030.

• Portfolio prioritization: internal spend shifts away from zelenectide in mUC toward BT5528.

What They're Saying

• CEO Kevin Lee: regulators indicated Duravelo-2’s current Phase II/III registrational design is “no longer considered acceptable as an approval path.”

• Lee: “Preliminary discussions with regulatory agencies have outlined several potential paths” forward, but Bicycle has “reached the difficult decision to deprioritise this programme for internal development.”

What's Next

• Duravelo-2 will be converted into a randomized Phase II as Bicycle evaluates alternative regulatory paths for zelenectide pevedotin in mUC.

• Expect increased emphasis on BT5528 clinical execution and data generation to support differentiation of the EphA2 Bicycle drug conjugate platform.

• Potential partnering: deprioritization “for internal development” leaves open the possibility of external collaboration or licensing for the Nectin-4 asset.